A new governance for Ad Scientiam

6 janvier 2022

Matthieu Lamy becomes President of Ad Scientiam, a pioneer in digital biomarkers. He knows the company well, having joined it five years ago to develop the US market before becoming CEO in 2020. He is now at the helm of a rapidly evolving company that aims to become the international leader in digital biomarkers for monitoring serious and disabling diseases. He is supported by Dr. Saad ZinaÏ as Medical Director.


MSCopilot®: New clinical results confirm central role of digital biomarkers in the monitoring of patients with multiple sclerosis Our news